Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM

Hunter, Laura; Dargan, Paul I.; Benzie, Andrew; White, John Albert

doi:10.1136/postgradmedj-2012-131428

Cited by 83 publications

(64 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Self-reported surveys of convenience samples have consistently found that use of recreational drugs in the LGBT population is significantly higher than among WSW or heterosexual adults (53,54), . This pattern is also replicated in MSM attending sexual health clinics (55). A systematic review of 23 studies found only use of methamphetamine and binge alcohol consumption to be significantly associated with increased sexual risk (56).…”

Section: Identification Of Problematic Recreational Drug and Alcohol Usementioning

confidence: 67%

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

et al. 2018

View full text Add to dashboard Cite

This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is likely to be of relevance in all sexual health settings, including general practice and Contraception and Sexual Health (CASH) services, where men who have sex with men (MSM) seek sexual health care or where addressing the sexual health needs of MSM may have public health benefits. For the purposes of this document, MSM includes all gay, bisexual and all other males who have sex with other males and both cis and trans men. This document does not provide guidance on the treatment of particular conditions where this is covered in other British Association for Sexual Health and HIV (BASHH) Guidelines but outlines best practice in multiple aspects of the sexual health care of MSM. Where prevention of sexually transmitted infections including HIV can be addressed as an integral part of clinical care, this is consistent with the concept of combination prevention and is included. The document is designed primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design and delivery of services with the aim of supporting clinicians and commissioners in providing effective services. Methodology This document was produced in accordance with the guidance set out in the BASHH CEG’s document ‘Framework for guideline development and assessment’ published in 2010 at http://www.bashh.org/guidelines and with reference to the Agree II instrument. Following the production of the updated framework in April 2015, the GRADE system for assessing evidence was adopted and the draft recommendations were regraded. Search strategy (see also Appendix 1) Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given to peer-reviewed papers published in scientific journals, although for many issues evidence includes conference abstracts listed on the Embase database. In addition, for ‘Identification of problematic recreational drug and alcohol use’ section and ‘Sexual problems and dysfunctions in MSM’ section, searches included PsycINFO. Methods Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was given to randomised controlled trial and systematic review evidence, and recommendations made and graded on the basis of best available evidence. Piloting and feedback The first draft of the guideline was circulated to the writing group and to a small group of relevant experts, third sector partners and patient representatives who were invited to comment on the whole document and specifically on particular sections. The revised draft was reviewed by the CEG and then reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. The final draft was piloted before publication. Guideline update The guidelines will be reviewed and revised in five years’ time, 2022.

show abstract

Section: Identification Of Problematic Recreational Drug and Alcohol Usementioning

confidence: 67%

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[2] It is recognised that MSM are more likely to take drugs than the general population. [3] In the United States and Australia the practice is known as 'party and play' (PNP) and is more common in urban areas with a large gay population. [4,5] Whilst chemsex is not a new phenomenon, healthcare professionals are worried that increased availability and accessibility of drugs and sex through websites and mobile applications has increased the acceptability, fashionableness and incidence of chemsex.…”

Section: Introductionmentioning

confidence: 99%

An observed rise in γ-hydroxybutyrate-associated deaths in London: Evidence to suggest a possible link with concomitant rise in chemsex

Hockenhull

Murphy

Paterson

2017

Forensic Science International

View full text Add to dashboard Cite

“…These patterns are echoed in a survey of attendees at genito-urinary clinics in July-September 2011 conducted in London which found higher rates of lifetime and last month use of both GHB and GBL by gay men than in heterosexual males. Lifetime use of GHB and GBL amongst gay men was 22.7% and 16.1% respectively; last month rates were 2.4% and 3.1% (Hunter et al, 2014). Lifetime use of GHB/GBL amongst gay males in the south London boroughs of Lambeth, Southwark and Lewisham between August 2013 and March 2014 was 30.6%, with 20.1% using in the previous year and 10.5% in the previous 4 weeks (Bourne et al, 2014).…”

Section: Recreational Use In the Ukmentioning

confidence: 99%

Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use

Corkery

Loi

Claridge

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Misuse of gamma hydroxybutrate (GHB) and gamma butyrolactone (GBL) has increased greatly since the early 1990s, being implicated in a rising number of deaths. This paper reviews knowledge on GHB and derivatives, and explores the largest series of deaths associated with their non-medical use. Descriptive analyses of cases associated with GHB/GBL and 1,4-butanediol (1,4-BD) use extracted from the UK's National Programme on Substance Abuse Deaths database. From 1995 to September 2013, 159 GHB/GBL-associated fatalities were reported. Typical victims: White (92%); young (mean age 32 years); male (82%); with a drug misuse history (70%). Most deaths (79%) were accidental or related to drug use, the remainder (potential) suicides. GHB/GBL alone was implicated in 37%; alcohol 14%; other drugs 28%; other drugs and alcohol 15%. Its endogenous nature and rapid elimination limit toxicological detection. Post-mortem blood levels: mean 482 (range 0-6500; SD 758)mg/L. Results suggest significant caution is needed when ingesting GHB/GBL, particularly with alcohol, benzodiazepines, opiates, stimulants, and ketamine. More awareness is needed about risks associated with consumption.

show abstract

Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM

Cited by 83 publications

References 24 publications

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

An observed rise in γ-hydroxybutyrate-associated deaths in London: Evidence to suggest a possible link with concomitant rise in chemsex

Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use

Contact Info

Product

Resources

About